Akari Therapeutics (AKTX)

• Market cap: $24.1M
• 1 day: -1.71%
• 5 days: -9.77%
• 1 month: -9.69%
• 3 months: -34.54%
• 6 months: -45.61%
• Year to date: -38.87%
• 1 year: -65.27%
• 5 years: -97.82%
• 10 years: -99.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Employees: 12